CN113226347A - 印楝提取物以及尿石素a和b的协同组合的抗糖尿病活性 - Google Patents

印楝提取物以及尿石素a和b的协同组合的抗糖尿病活性 Download PDF

Info

Publication number
CN113226347A
CN113226347A CN201980085374.9A CN201980085374A CN113226347A CN 113226347 A CN113226347 A CN 113226347A CN 201980085374 A CN201980085374 A CN 201980085374A CN 113226347 A CN113226347 A CN 113226347A
Authority
CN
China
Prior art keywords
neem
aqueous extract
levels
weeks
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980085374.9A
Other languages
English (en)
Chinese (zh)
Inventor
穆鲁加南达姆·A·韦拉拉格温
昌丹·K·森
桑耶西·R·卡利丁迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Natreon Inc
Original Assignee
Natreon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natreon Inc filed Critical Natreon Inc
Publication of CN113226347A publication Critical patent/CN113226347A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980085374.9A 2018-11-05 2019-11-05 印楝提取物以及尿石素a和b的协同组合的抗糖尿病活性 Pending CN113226347A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201841041788 2018-11-05
IN201841041788 2018-11-05
US16/672,743 2019-11-04
US16/672,743 US20200138892A1 (en) 2018-11-05 2019-11-04 Anti-diabetic activity of neem extract and synergistic combinations of urolithins a and b
PCT/US2019/059774 WO2020097014A1 (en) 2018-11-05 2019-11-05 Anti-diabetic activity of neem extract and synergistic combinations of urolithins a and b

Publications (1)

Publication Number Publication Date
CN113226347A true CN113226347A (zh) 2021-08-06

Family

ID=70460249

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980085374.9A Pending CN113226347A (zh) 2018-11-05 2019-11-05 印楝提取物以及尿石素a和b的协同组合的抗糖尿病活性

Country Status (10)

Country Link
US (1) US20200138892A1 (https=)
EP (1) EP3876968A4 (https=)
JP (1) JP2022536223A (https=)
KR (1) KR20210096121A (https=)
CN (1) CN113226347A (https=)
AU (1) AU2019377432A1 (https=)
BR (1) BR112021008725A2 (https=)
CA (1) CA3118926A1 (https=)
MX (1) MX2021005246A (https=)
WO (1) WO2020097014A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220098228A1 (en) * 2020-09-28 2022-03-31 Natreon, Inc. Methods and compositions for improving the immune system and providing immuno-protection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006030426A1 (en) * 2004-09-13 2006-03-23 Amcod Limited Herbal compositions for treatment of diabetes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8206753B2 (en) * 2001-06-20 2012-06-26 Metaproteomics, Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
JP2005325025A (ja) * 2004-05-12 2005-11-24 Green Kanpo Seiyaku Kk 糖尿病予防・治療組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006030426A1 (en) * 2004-09-13 2006-03-23 Amcod Limited Herbal compositions for treatment of diabetes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HUANG,PL: "A comprehensive definition for metabolic syndrome", 《DISEASE MODELS& MECHANISMS》 *
PRATIBHA KALANI等: ""EFFECT OF TRIGONELLA FOENUM-GRAECUM (METHI) AND AZADIRACHTA INDICA (NEEM) AS AN ADD-ON TREATMENT IN MANAGEMENT OF NON INSULIN DEPENDENT DIABETES MELLITUS (TYPE 2 DM)", 《WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES》 *

Also Published As

Publication number Publication date
EP3876968A4 (en) 2022-09-14
WO2020097014A1 (en) 2020-05-14
US20200138892A1 (en) 2020-05-07
BR112021008725A2 (pt) 2021-08-03
CA3118926A1 (en) 2020-05-14
KR20210096121A (ko) 2021-08-04
EP3876968A1 (en) 2021-09-15
AU2019377432A1 (en) 2021-06-10
JP2022536223A (ja) 2022-08-15
MX2021005246A (es) 2021-09-08

Similar Documents

Publication Publication Date Title
Matthias et al. Echinacea alkamide disposition and pharmacokinetics in humans after tablet ingestion
US20120093942A1 (en) Pharmaceutical composition for treating nephropathy and healthy food comprising herb extracts
Majeed et al. Novel Emblica officinalis extract containing β-glucogallin vs. metformin: a randomized, open-label, comparative efficacy study in newly diagnosed type 2 diabetes mellitus patients with dyslipidemia
KR20130019352A (ko) 꾸지뽕나무 줄기 추출물을 함유하는 아토피 질환 치료용 조성물
Abdoli et al. Anti-hyperglycemic effect of aqueous extract of Juglans regia L. leaf (walnut leaf) on type 2 diabetic patients: a randomized controlled trial
CN113616688B (zh) 一种修复肾脏损伤的鹅肌肽组合物及其应用
Sakhaei et al. Cardiovascular and renal effects of Hibiscus Sabdariffa Linnaeus. in patients with diabetic nephropathy: A randomized, double-blind, controlled trial
US10183047B2 (en) Chromium-containing compositions in combination with Phyllanthus emblica and shilajit having synergistic effects for improving endothelial function and cardiovascular health
CN113226347A (zh) 印楝提取物以及尿石素a和b的协同组合的抗糖尿病活性
JP2009007328A (ja) 抗アレルギー性組成物
US20200113960A1 (en) Compositions for preventing or treating diseases or disorders associated with neuro-inflammation, neuro-apoptosis, or neuro-oxidative damage and uses thereof
US20160015740A1 (en) Chromium-containing compositions for improving endothelial function and cardiovascular health
Khaled Effect of ascorbic acid, Balanites aegyptiaca, and strawberry supplementation on glycemic control and renal function biomarkers
Haider et al. Efficacy and safety of Plantago major seeds in patients with diabetic nephropathy: A randomized open-labeled controlled clinical trial
Gupta et al. Nutraceuticals for diabetes and glucose balance
RU2238755C1 (ru) Лечебно-профилактическое средство, обладающее гепатопротекторным, холестерино- и сахарорегулирующим действием (варианты)
KR20040092232A (ko) 성기능 개선용 홍삼복합물, 이의 제조방법 및 이의 용도
Basuny et al. Efficacy of the traditional use of Olive Leaves decoction as Anti-diabetic Agent in Geriatrics.
CN105770087B (zh) 一种治疗糖尿病、高脂血症、原发性高血粘度的蒙药组合物
US11992512B2 (en) Composition and method for treating dyspepsia
WO2016186695A1 (en) Synergistic compositions containing chromium with phyllanthus emblica and shilajit for improving endothelial function and cardiovascular health
Basirat et al. The effect of Achillea millefolium a widely used plant in Persian Medicine on hemoglobin glycosylate and neuropathy symptoms in type 2 diabetic patients: A randomized clinical trial
WO2002069971A1 (en) Pharmaceutical compositions and dietary supplements for treatment or improvement of arthitis
Dilawar et al. Management of Shvitra (Vitiligo) By An Ayurvedic Regime-A Case Study
WO2024062077A1 (en) Phlorotannins and alpha-fucans to treat type 2 diabetes mellitus

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination